Menu
Search
|

Menu

Close
X

Ucb SA UCB.BR (Brussels Stock Exchange)

65.26 EUR
+0.40 (+0.62%)
As of 11:35 AM EDT
Previous Close 64.86
Open 64.96
Volume 409,832
3m Avg Volume 306,208
Today’s High 65.36
Today’s Low 64.58
52 Week High 80.68
52 Week Low 64.58
Shares Outstanding (mil) 194.51
Market Capitalization (mil) 13,833.24
Forward P/E 20.48
Dividend (Yield %) 1.21 ( 1.16 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.67 Mean rating from 18 analysts

KEY STATS

Revenue (mm, EUR)
FY19
2,323
FY18
4,632
FY17
4,530
FY16
4,147
EPS (EUR)
FY19
2.191
FY18
4.204
FY17
3.994
FY16
2.883
*Note: Units in Millions of Euro
**Note: Units in Euro

KEY RATIOS

Price to Earnings (TTM)
vs sector
20.48
33.85
Price to Sales (TTM)
vs sector
2.95
7.90
Price to Book (MRQ)
vs sector
2.07
4.38
Price to Cash Flow (TTM)
vs sector
14.13
23.70
Total Debt to Equity (MRQ)
vs sector
21.41
17.64
LT Debt to Equity (MRQ)
vs sector
15.45
12.61
Return on Investment (TTM)
vs sector
8.31
12.69
Return on Equity (TTM)
vs sector
10.45
17.13

EXECUTIVE LEADERSHIP

Jean-Christophe Tellier
Chairman of the Executive Committee, Chief Executive Officer, Executive Director, Since 2015
Salary: --
Bonus: --
Evelyn Diego du Monceau de Bergendal
Non-Executive Chair of the Board, Since 2017
Salary: --
Bonus: --
Pierre Gurdjian
Independent Non-Executive Vice Chairman of the Board, Since 2017
Salary: --
Bonus: --
Detlef Thielgen
Executive Vice President, Chief Financial Officer, Member of the Executive Committee, Since 2007
Salary: --
Bonus: --
Charl van Zyl
Executive Vice President, Chief Operating Officer, Member of the Executive Committee, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

Allee de la Recherche, 60
ANDERLECHT     1070

Phone: +322.5599999

Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.

SPONSORED STORIES